source
- Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s PatientsCognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
- nChroma Bio halts sole clinical trial and cuts staff by halfTwo Boston-area biotech founders merged their companies a few years ago to create nChroma Bio, hoping the combined effort would weather a weak market for genetic‑medicine firms. The company has no…